TEL/AML1 Quantitative Test: Advanced Genetic Analysis for Leukemia Detection
Understanding the TEL/AML1 Quantitative Test
The TEL/AML1 Quantitative test represents a cutting-edge approach in molecular diagnostics, specifically designed to detect and measure the presence of the TEL/AML1 fusion gene. This genetic abnormality plays a crucial role in the development and progression of certain types of leukemia, particularly childhood acute lymphoblastic leukemia (ALL). The test’s quantitative nature allows healthcare providers to not only identify the presence of this fusion gene but also measure its exact quantity, providing valuable information for diagnosis, treatment planning, and ongoing monitoring.
What the TEL/AML1 Quantitative Test Measures
This sophisticated genetic test specifically targets and quantifies the TEL/AML1 fusion gene, which results from a chromosomal translocation between chromosomes 12 and 21. The test measures:
- Presence of TEL/AML1 fusion gene transcripts
- Quantitative levels of fusion gene expression
- Molecular response to treatment interventions
- Minimal residual disease (MRD) monitoring
Technical Methodology
Utilizing advanced Real-Time PCR (Polymerase Chain Reaction) technology, the test provides highly sensitive and specific detection of the TEL/AML1 fusion gene. This method allows for precise quantification of genetic material, enabling clinicians to track disease progression and treatment response with exceptional accuracy.
Who Should Consider the TEL/AML1 Quantitative Test?
This test is particularly important for individuals experiencing or at risk for:
- Patients with suspected or newly diagnosed acute lymphoblastic leukemia
- Children presenting with unexplained symptoms such as persistent fatigue, frequent infections, or unusual bruising
- Individuals with abnormal blood counts requiring further investigation
- Patients undergoing leukemia treatment who require monitoring of treatment response
- Individuals in remission who need minimal residual disease assessment
- Patients with family history of hematological malignancies
Common Symptoms and Indicators
Patients who may benefit from this test often present with symptoms including persistent fatigue, recurrent infections, unexplained bruising or bleeding, bone pain, swollen lymph nodes, and unexplained weight loss. Early detection through genetic testing can significantly impact treatment outcomes.
Benefits of TEL/AML1 Quantitative Testing
Choosing the TEL/AML1 Quantitative test offers numerous advantages for patients and healthcare providers:
- Early and Accurate Diagnosis: Provides definitive identification of TEL/AML1 fusion gene presence
- Treatment Guidance: Helps determine the most appropriate therapeutic approach
- Prognostic Information: Offers insights into disease progression and potential outcomes
- Treatment Monitoring: Enables precise tracking of treatment effectiveness
- Minimal Residual Disease Detection: Identifies low levels of disease not detectable by conventional methods
- Personalized Medicine: Supports development of targeted treatment strategies
Understanding Your Test Results
Interpreting TEL/AML1 Quantitative test results requires careful consideration by qualified healthcare professionals. Results typically indicate:
Positive Results
A positive result confirms the presence of the TEL/AML1 fusion gene, which is strongly associated with a specific subtype of acute lymphoblastic leukemia. The quantitative measurement provides information about the level of fusion gene expression, which can help guide treatment intensity and duration.
Negative Results
A negative result indicates the absence of detectable TEL/AML1 fusion gene, suggesting that the patient’s condition may be due to other genetic abnormalities or conditions. However, clinical correlation with other diagnostic findings is essential.
Quantitative Values
The numerical values provided in the test report represent the quantity of TEL/AML1 fusion gene transcripts. These values are interpreted in the context of:
- Baseline measurements at diagnosis
- Treatment response over time
- Comparison with established clinical thresholds
- Integration with other laboratory and clinical findings
Test Pricing and Availability
| Test Component | Price (USD) |
|---|---|
| Discount Price | $150 |
| Regular Price | $200 |
Test Specifications
- Turnaround Time: 3-4 days
- Sample Type: Bone marrow / Peripheral blood (Transport immediately)
- Test Components: EDTA Vacutainer (2ml)
- Methodology: Real Time PCR
Pre-Test Instructions
The TEL/AML1 Quantitative test requires a Doctor’s prescription for most cases. Please note that prescription requirements may not apply for surgery and pregnancy cases or individuals planning to travel abroad. Consult with your healthcare provider for specific preparation instructions.
Nationwide Testing Availability
We proudly serve patients across the United States with convenient testing locations in all major cities including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our extensive network ensures that quality genetic testing is accessible to patients nationwide.
Take Action for Your Health Today
Don’t wait to get the answers you need for proper leukemia diagnosis and management. The TEL/AML1 Quantitative test provides critical genetic information that can significantly impact treatment decisions and outcomes. Our team of genetic specialists and healthcare professionals is ready to assist you with comprehensive testing and personalized care.
Book your TEL/AML1 Quantitative test today by calling +1(267) 388-9828 or schedule your appointment online. Take the first step toward accurate diagnosis and effective treatment planning.
